Peroxisome proliferator-activated receptor gamma agonists in the prevention and treatment of murine systemic lupus erythematosus

Immunology

Volumn 142, Issue 3, 2014, Pages 363-373

  Aprahamian, Tamar R ^a   Bonegio, Ramon G ^a   Weitzner, Zachary ^a   Gharakhanian, Raffi ^a   Rifkin, Ian R ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Animal models; Atherosclerosis; Systemic lupus erythematosus

Indexed keywords

ADIPONECTIN; CHOLESTEROL; PIOGLITAZONE; ROSIGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; AUTOIMMUNITY; CAUSE OF DEATH; CHOLESTEROL DIET; CONTROLLED STUDY; DIET; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; FOOD INTAKE; GENE EXPRESSION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THERAPY EFFECT; TREATMENT DURATION; WESTERN DIET;

ANIMAL MODELS; ATHEROSCLEROSIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; APOLIPOPROTEINS E; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 84901999850     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12256     Document Type: Article

References (35)

1. Kotzin BL. Systemic lupus erythematosus. Cell 1996; 85:303-6.
2. Liu Z, Davidson A. Taming lupus - a new understanding of pathogenesis is leading to clinical advances. Nat Med 2012; 18:871-82.
3. Merrill JT, Erkan D, Buyon JP. Challenges in bringing the bench to bedside in drug development for SLE. Nat Rev Drug Discov 2004; 3:1036-46.
4. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355:2427-43.
5. Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2002; 2:748-59.
6. Libby P, Plutzky J. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-γ agonists. Am J Cardiol 2007; 99:27B-40B.
7. Straus DS, Glass CK. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol 2007; 28:551-8.
8. Aprahamian T, Bonegio RG, Richez C, Yasuda K, Chiang LK, Sato K, Walsh K, Rifkin IR. The peroxisome proliferator-activated receptor γ agonist rosiglitazone ameliorates murine lupus by induction of adiponectin. J Immunol 2009; 182:340-6.
9. Venegas-Pont M, Sartori-Valinotti JC, Maric C et al. Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus. Am J Physiol Regul Integr Comp Physiol 2009; 296:R1282-9.
10. Zhao W, Thacker SG, Hodgin JB et al. The peroxisome proliferator-activated receptor γ agonist pioglitazone improves cardiometabolic risk and renal inflammation in murine lupus. J Immunol 2009; 183:2729-40.
11. Roszer T, Menendez-Gutierrez MP, Lefterova MI, Alameda D, Nunez V, Lazar MA, Fischer T, Ricote M. Autoimmune kidney disease and impaired engulfment of apoptotic cells in mice with macrophage peroxisome proliferator-activated receptor γ or retinoid X receptor α deficiency. J Immunol 2011; 186:621-31.
12. Juarez-Rojas JG, Medina-Urrutia AX, Jorge-Galarza E et al. Pioglitazone improves the cardiovascular profile in patients with uncomplicated systemic lupus erythematosus: a double-blind randomized clinical trial. Lupus 2012; 21:27-35.
13. Aprahamian T, Rifkin I, Bonegio R, Hugel B, Freyssinet JM, Sato K, Castellot JJ Jr, Walsh K. Impaired clearance of apoptotic cells promotes synergy between atherogenesis and autoimmune disease. J Exp Med 2004; 199:1121-31.
14. Nikpour M, Urowitz MB, Gladman DD. Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am, 2005; 31:329-54, vii-viii.
15. Cohen PL, Eisenberg RA. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 1991; 9:243-69.
16. Komori H, Furukawa H, Mori S et al. A signal adaptor SLAM-associated protein regulates spontaneous autoimmunity and Fas-dependent lymphoproliferation in MRL-Faslpr lupus mice. J Immunol 2006; 176:395-400.
17. Slater NG, Cameron JS, Lessof MH. The Crithidia luciliae kinetoplast immunofluorescence test in systemic lupus erythematosus. Clin Exp Immunol 1976; 25:480-6.
18. Maeda N, Takahashi M, Funahashi T et al. PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50:2094-9.
19. Andrews BS, Eisenberg RA, Theofilopoulos AN et al. Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J Exp Med 1978; 148:1198-215.
20. Henegar JR, Bigler SA, Henegar LK, Tyagi SC, Hall JE. Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol 2001; 12:1211-7.
21. Ruggiero C, Ehrenshaft M, Cleland E, Stadler K. High-fat diet induces an initial adaptation of mitochondrial bioenergetics in the kidney despite evident oxidative stress and mitochondrial ROS production. Am J Physiol Endocrinol Metab 2011; 300:E1047-58.
22. Skaggs BJ, Hahn BH, McMahon M. Accelerated atherosclerosis in patients with SLE - mechanisms and management. Nat Rev Rheumatol 2012; 8:214-23.
23. Valero-Gonzalez S, Castejon R, Jimenez-Ortiz C, Rosado S, Tutor-Ureta P, Vargas JA, Yebra-Bango M. Increased arterial stiffness is independently associated with metabolic syndrome and damage index in systemic lupus erythematosus patients. Scand J Rheumatol 2013; 43:54-8.
24. Gabriel CL, Smith PB, Mendez-Fernandez YV, Wilhelm AJ, Ye AM, Major AS. Autoimmune-mediated glucose intolerance in a mouse model of systemic lupus erythematosus. Am J Physiol Endocrinol Metab 2012; 303:E1313-24.
25. Parker B, Bruce I. SLE and metabolic syndrome. Lupus 2013; 22:1259-66.
26. Parker B, Urowitz MB, Gladman DD et al. Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis 2013; 72:1308-14.
27. Chung CP, Avalos I, Oeser A, Gebretsadik T, Shintani A, Raggi P, Michael Stein C. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis 2007; 66:208-14.
28. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356:2457-71.
29. Mahaffey KW, Hafley G, Dickerson S et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. Am Heart J 2013; 166:240-9.e1.
30. Choi JH, Banks AS, Kamenecka TM et al. Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature 2011; 477:477-81.
31. Zhao W, Thacker SG, Hodgin JB et al. The peroxisome proliferator-activated receptor γ agonist pioglitazone improves cardiometabolic risk and renal inflammation in murine lupus. J Immunol 2009; 183:2729-40.
32. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366:1279-89.
33. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356:2457-71.
34. Ajuwon KM, Banz W, Winters TA. Stimulation with Peptidoglycan induces interleukin 6 and TLR2 expression and a concomitant downregulation of expression of adiponectin receptors 1 and 2 in 3T3-L1 adipocytes. J Inflamm (Lond) 2009; 6:8.
35. Saito Y, Fujioka D, Kawabata K et al. Statin reverses reduction of adiponectin receptor expression in infarcted heart and in TNF-α-treated cardiomyocytes in association with improved glucose uptake. Am J Physiol Heart Circ Physiol 2007; 293:H3490-7.